)
McKesson (MCK) investor relations material
McKesson Q1 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Revenues for Q1 FY27 rose 8% to $105.4B, driven by North American Pharmaceutical and Oncology & Multispecialty growth, while adjusted EPS increased 20% to $9.93 and GAAP EPS declined 18% to $5.15 due to a $293M charge related to Medical-Surgical Solutions.
Raised full-year adjusted EPS guidance to $44.20–$45.00, reflecting 13–15% growth and confidence in business momentum.
Advanced the planned separation and rebranding of Medical-Surgical Solutions as Wellverse, including a 13% minority sale to Apollo Funds for $1.25B.
Returned $2.6B to shareholders, including $2.5B in share repurchases and a 15% dividend increase to $0.94 per share.
Continued strategic focus on AI, technology investments, and operational efficiency, including leadership changes and enterprise-wide AI training.
Financial highlights
Gross profit rose 13% to $3.7B; operating profit up 16% to $1.7B; adjusted earnings totaled $1.18B, up 14% year-over-year.
Net income attributable to the company was $614M, down 22% year-over-year, with diluted GAAP EPS at $5.15.
Operating expenses increased 10% to $2.1B, but operating leverage improved by 150 basis points year-over-year.
Free cash flow for the quarter was negative $372M, but trailing 12-month free cash flow was $6.15B.
Returned $2.6B to shareholders via share repurchases and dividends; board approved a 15% dividend increase.
Outlook and guidance
Fiscal 2027 adjusted EPS outlook raised to $44.20–$45.00, implying 13–15% growth; no GAAP EPS guidance due to unpredictability of certain adjustments.
Revenue growth expected at 5–9%, operating profit growth at 9–13%.
Segment guidance: North American Pharmaceutical revenue up 4–8%, Oncology & Multispecialty up 14.5–18.5%, Prescription Technology Solutions up 2.5–6.5%, Medical-Surgical Solutions up 1–6%.
Free cash flow guidance of $4.5–$4.9B; $5B in share repurchases planned for FY27.
Management expects available cash, investments, and credit facilities to be sufficient for short- and long-term needs.
- Proxy statement covers annual meeting proposals, board governance, and voting rights.MCK
Proxy filing - Key votes include board elections, auditor ratification, and executive pay approval.MCK
Proxy filing - Proxy details strong financials, board refreshment, and robust pay-for-performance alignment.MCK
Proxy filing - Specialty drugs, biosimilars, and automation drive growth and margin expansion into 2027.MCK
Bank of America Global Healthcare Conference 2026 - FY26 delivered double-digit revenue and EPS growth, with robust FY27 outlook and portfolio optimization.MCK
Q4 2026 - Revenue up 11%, adjusted EPS up 16%, and fiscal 2026 EPS guidance raised to $38.80–$39.20.MCK
Q3 2026 - Raised FY26 EPS guidance, specialty growth, and segment separation drive long-term value.MCK
Investor Day 2025 - Revenue up 21%, Adjusted EPS up 13%, 2025 guidance raised, $2.2B returned to shareholders.MCK
Q2 2025 - Adjusted EPS up 8% on 6% revenue growth; guidance, dividend, and buyback all raised.MCK
Q1 2025
Next McKesson earnings date
Next McKesson earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage